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The  matricellular  protein  WISP1  is  a member  of the  CCN  protein  family.  It is induced  by  WNT1  and  is  a
downstream  target  of  -catenin.  WISP1  is  expressed  during  embryonic  development,  wound  healing  and
tissue  repair.  Aberrant  WISP1  expression  is  associated  with  various  pathologies  including  osteoarthri-
tis,  ﬁbrosis  and  cancer.  Its  role  in tumor  progression  and  clinical  outcome  makes  WISP1 an  emerging
candidate  for  the  detection  and  treatment  of  tumors.eywords:
NT1 inducible signaling pathway protein 1
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license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
The WNT1 inducible signaling pathway protein 1, also known as
CN4 or Elm1 is a cysteine-rich, matricellular protein that belongs
o the CCN family (Hashimoto et al., 1998; Jun and Lau, 2011). The
cronym “CCN” is derived from the names of the ﬁrst three fam-
ly members: CYsteine-Rich 61 (CYR61/CCN1), Connective Tissue
rowth Factor (CTGF/CCN2) and Nephroblastoma OVer-expressed
NOV/CCN3) (Jun and Lau, 2011). WISP1 was originally identiﬁed
s a downstream target of WNT1 and -catenin, and contributes to
-catenin-mediated tumorigenesis (Pennica et al., 1998; Xu et al.,
000).
Deregulation of WISP1 signaling may  result in various patholo-
ies including osteoarthritis, ﬁbrosis and cancer. In a previous
eview, the role of WISP1 in development and disease was  dis-
ussed (Berschneider and Konigshoff, 2011). Here, we  focus on the
mpact of WISP1 in tumor progression and summarize recent stud-
es based on which WISP1 holds promise as a diagnostic marker
nd/or therapeutic target.∗ Corresponding author at: Friedrich Miescher Institute for Biomedical Research,
aulbeerstrasse 66, CH-4058 Basel, Switzerland. Tel.: +41 61 697 24 94.
E-mail address: Irem.Guerbuez@fmi.ch (I. Gurbuz).
ttp://dx.doi.org/10.1016/j.biocel.2015.03.007
357-2725/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article un2. Structure
CCN proteins possess a conserved modular structure consist-
ing of an amino-terminal secretory signal peptide followed by four
structural domains: an insulin-like growth factor binding protein-
like module (IGFBP), a von Willebrand factor type C repeat (VWC), a
thrombospondin-homology type 1 repeat (TSP1), and a C-terminal
cysteine-knot-containing (CT) domain (Jun and Lau, 2011). A non-
conserved, protease-sensitive hinge region is located between VWC
and TSP1 domains (Jun and Lau, 2011). Except CCN5, which lacks
the CT module (Pennica et al., 1998), all CCN proteins contain the
four complete structural modules (Fig. 1).
CCN protein variants that lack certain domains play distinct bio-
logical roles and have been implicated in several pathologies (Jun
and Lau, 2011). Alternative splicing results in WISP1v lacking exon
3 and thus the VWC  domain (Tanaka et al., 2001). This truncated
variant has been detected in scirrhous gastric carcinoma (Tanaka
et al., 2001) and invasive cholangiocarcinoma (Tanaka et al., 2003).
Moreover, in addition to full length WISP1 and WISP1v, two
hepatocellular carcinoma cell lines and a human chondrosarcoma-
derived chondrocytic cell line express further shorter variants,
WISP-1ex3-4 (Cervello et al., 2004) and WISP1vx (Yanagita et al.,
2007), respectively. Models of all described WISP1 variants are
shown in Fig. 1.
The full length WISP1 protein consists of 367 aminoacids with
a predicted molecular mass of 40 kDa, has 38 conserved cysteine
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Modular structure of CCN proteins. Full length CCN4/WISP1 and truncated
variants are shown in orange. WISP1v is a gene product formed by alternative
splicing that lacks exon 3, hence the VWC  domain (Tanaka et al., 2001). WISP1vx
lacks VWC  and TSP1 domains and part of the IGFBP domain (23 bp shorter than the
full-length exon). Owing to a frame-shift, the IGFBP/CT fusion coding frame is not
translated properly after the alternative splice site. The protein product is a single
IGFBP module, in which eight C-terminal amino acid residues are removed, and an
extra 14 residues are added in their place (Yanagita et al., 2007). WISP1ex3-4 splice
variant is a product of joining of exons 2 and 5 with a frameshift that led to a prema-
ture  stop. As a result, the predicted protein has only the ﬁrst module (Cervello et al.,
2004). SP: signal peptide, IGFBP: insulin growth factor binding protein, VWC: van
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tillebrand Factor C, TSP1: thrombospondin type 1 repeat, CT: C-terminal domain.
For interpretation of the references to color in this ﬁgure legend, the reader is
eferred to the web  version of this article.)
esidues and four potential N-linked glycosylation sites (Pennica
t al., 1998; Berschneider and Konigshoff, 2011). Indeed, it was
bserved that WISP1 is glycosylated and that the pattern of gly-
osylation differs between cancer cells and normal ﬁbroblasts
discussed in Soon et al., 2003). Furthermore, overexpression of
ISP1 in mammalian cells and external addition of the recombi-
ant WISP1 produced in Escherichia coli (E.coli), lacking mammalian
ost-translational modiﬁcations, had different biological effects
n cells (Inkson et al., 2008). According to these results, post-
ranslational modiﬁcations seem to affect WISP1 function.
. Regulation and biological function
WISP1 expression is regulated by different signaling pathways
nd is sensitive to different biochemical cues as well as extracel-
ular perturbations. Previous work from our group showed that
ISP1 is induced by megakaryoblastic leukemia protein 1 (Mkl1)
n a serum response factor-independent, SAP domain-dependent
anner and it was found to be part of a gene signature implicated
n cell proliferation and motility elevated in breast cancer patients
ith poor survival (Gurbuz et al., 2014). Many genes of this sig-
ature, including WISP1 were shown to be mechano-responsive in
yclically stretched mouse mammary epithelial cells (Gurbuz et al.,
014). Furthermore, WISP1 was induced by mechanical stretch
n lung alveolar epithelial cells (Heise et al., 2011). Additionally,
ellular processes that modulate Wnt/-catenin signaling regu-
ate the expression of the downstream target genes, including
ISP1. In a rat model of alcohol-induced liver disease, it was  found
hat chronic alcohol feeding induces Wnt/-catenin signaling and
ISP1 upregulation, which in turn increases hepatocyte prolifer-
tion and promotes tumorigenesis (Mercer et al., 2014). A recent
tudy shows that overexpression of WISP1 contributes to the
evelopment of fractionated irradiation-induced radioresistance
n esophageal cancer cells in vitro and in vivo, and links WISP1 to
adiation, a phenomenon that is known to activate Wnt/-catenin
ignaling (Li et al., 2014).CCN family members regulate complex biological processes dur-
ng embryogenesis, wound healing and tissue repair (Berschneider
nd Konigshoff, 2011). WISP1 expression has been observed in
he developing skeleton and during bone healing in the adulthoodl of Biochemistry & Cell Biology 62 (2015) 142–146 143
(French et al., 2004). WISP1 mRNA was detected in the adult heart,
kidney, lung, pancreas, placenta, ovary, small intestine, and spleen.
Low or no expression was  seen in the brain, liver, skeletal mus-
cle, colon, peripheral blood leukocytes, prostate, testis, or thymus
(Pennica et al., 1998). WISP1 knockout (KO) mice show delayed
wound healing and cartilage development compared to wildtype
mice (Seventh international workshop on the CCN family of genes,
2014). Many reports support a function of WISP1 in tumor cell pro-
liferation, migration and survival in vitro, as well as tumor growth
and metastasis in vivo.
Recombinant WISP1 (Source: E. coli) treatment is shown to pro-
mote mitosis in irradiated esophageal cancer cells (Li et al., 2014)
and in human bone marrow stromal cells (hBMSCs; Inkson et al.,
2008). Likewise, recombinant WISP1 treatment (Source: mouse
myeloma cells) induces proliferation of alveolar epithelial cells and
adenocarcinomic human alveolar basal epithelial cells (Konigshoff
et al., 2009). Overexpression of WISP1 variants increases the growth
rate of mouse embryonic ﬁbroblasts (Tanaka et al., 2001), rat kidney
ﬁbroblasts (Xu et al., 2000), hBMSCs (Inkson et al., 2008) and human
esophageal cancer cells (Nagai et al., 2011). Dermal ﬁbroblasts iso-
lated from KO mice show impaired cell proliferation and migration
in vitro (Seventh international workshop on the CCN family of
genes, 2014). This seems to be different for melanoma cells. Mouse
melanoma cells expressing a high level of WISP1 showed slightly
slower in vitro and in vivo growth rates than cells expressing a low
level of the protein (Hashimoto et al., 1998). Furthermore, a recent
study shows that supplementation of recombinant WISP1 (Source:
mouse myeloma cells) in the culture medium has an inhibitory
effect on melanoma cell growth while migration is not affected
(Shao et al., 2011). The number of migrated gastric carcinoma cells
(Tanaka et al., 2001) and cholangiocarcinoma cells (Tanaka et al.,
2003) increased with exposure to WISP1v. Human prostate cancer
cells (Ono et al., 2013) and chondrosarcoma cells (Hou et al., 2011)
show increased migration and invasion toward WISP1 recombi-
nant protein (Source: E. coli), which suggests that WISP1 could
have chemotactic properties and might inﬂuence the homing of
cancer cells in case of metastasis. In support of these results, it
was reported that recombinant WISP1 treatment (Source: mouse
myeloma cells) induces epithelial to mesenchymal transition by
regulating marker gene expression and by increasing cell migra-
tion (Konigshoff et al., 2009). In contrast, WISP1 overexpression in
lung cancer cells leads to an inhibition of in vitro cell invasion and
motility, as well as lung metastasis (Soon et al., 2003).
How exactly WISP1 modulates cellular function and through
which receptors it transmits signals is unknown. Different inte-
grins have been identiﬁed as functional receptors for some CCN
proteins (Jun and Lau, 2011). Recent studies have conﬁrmed the
functional and physical interaction of WISP1 with integrins. It was
shown that WISP1 physically interacts with 51 Integrin, and that
its overexpression increases 5 expression in bone marrow stro-
mal  cells (Ono et al., 2011). Two  other binding partners of WISP1
are decorin and biglycan, members of a family of small leucine-
rich proteoglycans present in the extracellular matrix of connective
tissue (Desnoyers et al., 2001).
4. Expression in cancer and role in prognosis
CNN proteins are aberrantly expressed in numerous diseases,
including cancer (Jun and Lau, 2011). Generally, WISP1 expression
has been associated with the promotion of tumor progression, and
in a range of tumor types high WISP1 expression has been identiﬁed
within the tumor tissue compared to the healthy organ (summa-
rized in Table 1). Likewise, transcript proﬁling studies available
from the Oncomine database reveal increased WISP1 transcript
levels in a wide variety of cancers (Fig. 2). Moreover, WISP1 cor-
relates with poor prognosis in the majority of cancer incidences.
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Fig. 2. Aberrant WISP1 expression has been identiﬁed in different tumor types. Oncomine differential gene expression analysis (Normal vs Cancer, Human Genome U133
Affymetrix Array data, Affymetrix Probe ID: 206796 at, www.oncomine.org) revealed that WISP1 mRNA expression levels are higher within tumor tissue compared with
normal tissue in most of the cancer incidences. Results are represented with a box plot: the thick line represents the median value. Minimal and maximal values are plotted
as  dots. Fold changes (FC) between normal and tumor tissues are indicated. Number of samples analyzed is shown within brackets.
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Table  1
Cancer type Expression level
tumor versus
normal
Correlation of
WISP1 level
with prognosis
Reference
Breast Cancer Higher
Not known
Higher
Bad
Good
Not known
Xie et al. (2001),
Davies et al. (2007),
Klinke (2014)
Gastric
Adenocarcinoma
Higher Not known Bizama et al. (2014)
Brain Cancer Higher Bad Xie et al. (2004)
Pancreatic Cancer Higher Not known Cao et al. (2004),
Badea et al. (2008)
Head and Neck
Cancer
Higher Not known Chuang et al.
(2013)
Lung
Adenocarcinoma
Higher Not known Chen et al. (2007),
Yang et al. (2014)
Colorectal Cancer Higher Good
Bad
Khor et al. (2006),
Davies et al. (2010)
Rectal Cancer Higher Bad Tian et al. (2007)
Colon
Adenocarcinoma
Higher Not known Pennica et al.
(1998)
Chondrosarcoma Higher Not known Hou et al. (2011)
Endometrial
Endometrioid
Carcinoma
Higher Bad Tang et al. (2011)
Esophageal Cancer Higher Bad Nagai et al. (2011)
Scirrhous Carcinoma Higher Not known Tanaka et al. (2001)
Cholangiocarcinoma Higher Bad Tanaka et al. (2003)
Prostate Cancer Higher Good Ono et al. (2013)
Melanoma Lower Not known Shao et al. (2011)
Aggressive
Fibromatosis
Higher Bad Skubitz and Skubitz
(2004), Misemer
et al. (2013)
Publication details only provided for reports that are not listed under References:
Badea et al. (2008) Hepatogastroenterology 55(88): 2016–2027; Bizama et al. (2014)
Int  J Cancer 134(4): 755–764; Cao et al. (2004) Cancer Biol Ther 3(11): 1081–1089;
Chen et al. (2007) PLoS One 2(6): e534; Chuang et al. (2013). PloS One 8(10): e78022;
Klinke (2014) PLoS Comput Biol 10(1): e1003409; Misemer et al. (2014) Cancer Med
3(1): 81–90; Skubitz and Skubitz (2004) J Lab Clin Med  143(2): 89–98; Tang et al.
(2011) J Obstet Gynaecol Res 37(6): 606–612; Xie et al. (2004) Clin Cancer Res 10(6):
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a072–2081; Yang et al. (2014) Cancer Gene Ther 21(2): 74–82.
xceptionally, WISP1 levels in the primary prostate cancer stroma
nd in the patient’s sera decreases with increasing severity of the
ancer (Ono et al., 2013). In some cancers a role for WISP1 levels in
rognosis is controversial. For example, two independent studies
how that higher level of WISP1 is associated with poor histological
ifferentiation, tumor aggressiveness and poor clinical outcome in
olorectal and rectal carcinomas (Tian et al., 2007; Davies et al.,
010). In contrast, Khor et al. (2006) links WISP1 expression to
ell-differentiated colorectal tumors. A similar discrepancy is seen
hen analyzing WISP1 expression in breast cancer. Davies et al.
2007) show that the transcript levels are lower in node-positive
nd high-grade tumors and in patients with poor clinical outcome.l of Biochemistry & Cell Biology 62 (2015) 142–146 145
These results contradict a previously published study where it was
shown that high WISP1 mRNA levels correlate with an advanced
stage of breast cancer (Xie et al., 2001).
The crosstalk between tumor cells and the tumor stroma has
a remarkable impact on tumor progression. Cancer cells secrete
growth factors and proteases to activate surrounding stromal
cells to form a supportive environment for tumor progression
(Mueller and Fusenig, 2004). Activated ﬁbroblasts, also known
as carcinoma-associated ﬁbroblasts (CAFs), in turn modulate the
tumor microenvironment by secreting extracellular matrix pro-
teins and matrix degrading enzymes (Mueller and Fusenig, 2004).
WISP1 is upregulated in CAFs compared with ﬁbroblasts in the
adjacent normal tissue in colon cancer (Rupp et al., 2014) and in
breast cancer (Bauer et al., 2010). In many cancers and in WNT1
transgenic mice, WISP1 is localized to the tumor stroma surround-
ing the cancer cells (Pennica et al., 1998; Tanaka et al., 2001, 2003;
Bauer et al., 2010; Ono et al., 2013; Rupp et al., 2014). WISP1 over-
expressing rat kidney ﬁbroblasts are not able to form colonies in
the soft agar, however when they are injected into nude mice
they form tumors (Xu et al., 2000). These results suggest that the
paracrine interactions may  have a positive regulatory effect on
tumor growth and progression. In contrast, Shao et al. (2011) show
that WISP1 expression is stronger in quiescent ﬁbroblasts com-
pared with melanoma cells and “melanoma activated ﬁbroblasts”,
which suggest a negative regulatory effect of paracrine WISP1
signaling in melanoma.
5. Possible applications in cancer diagnosis and therapy
The differential expression status of WISP1 between the tumor
tissue and normal healthy tissue, as well as the correlation of its
expression with clinical outcome makes WISP1 a promising target
for the evaluation of clinical diagnosis and prognosis of cancers.
In particular, WISP1 could be exploited to predict different
stages of prostate cancer and thus serve as an alternative biomarker
to Prostate Speciﬁc Antigen (Ono et al., 2013). In early stages of
prostate cancer, WISP1 was detected not only in tissue biopsies but
also in sera from patients (Ono et al., 2013). In the future, WISP1
might be used as a tumor marker that is easy to detect by a simple
blood test.
In addition to its diagnostic potential, WISP1 can be utilized as a
therapeutic target. Targeting WISP1 by neutralizing antibodies neg-
atively regulates progression of certain cancers, including prostate
cancer and recurrent esophageal carcinoma after radiotherapy. In
mouse xenograft models of human prostate cancer cells, treatment
with WISP1 neutralizing antibodies reduces tumor growth as well
as metastasis to bone (Ono et al., 2013). In another study, deple-
tion of WISP1 by neutralizing antibodies cause mitotic catastrophe
in radioresistant esophageal cancer cells without affecting normal
cancer cells (Li et al., 2014). Blocking WISP1 interaction with its
partners, such as cancer-associated integrins, might be another
therapeutic strategy to inhibit WISP1-mediated tumor progres-
sion. Furthermore, ﬁnding ways to down-regulate its expression
might open new treatment opportunities. Since WISP1 expression
is known to be induced by Wnt/-catenin signaling as well as by
mechanical signals mediated by Mkl1, drugs constraining these
pathways may  help to alleviate WISP1-mediated effects on cancer
progression.
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